| Literature DB >> 34863201 |
Rosanna Herold1, René Scholtysik2, Selina Moroniak1, Christel Weiss3, Hiroshi Ishikawa4, Horst Schroten1, Christian Schwerk5.
Abstract
BACKGROUND: The Gram-negative bacterium Neisseria meningitidis (Nm) can cause meningitis in humans, but the host signalling pathways manipulated by Nm during central nervous system (CNS) entry are not completely understood.Entities:
Keywords: Blood-cerebrospinal fluid barrier; Host innate signalling; Host pathogen interaction; MAPK; Meningitis; Neisseria meningitidis
Mesh:
Year: 2021 PMID: 34863201 PMCID: PMC8643193 DOI: 10.1186/s12987-021-00288-7
Source DB: PubMed Journal: Fluids Barriers CNS ISSN: 2045-8118
Bacterial strains
| N. meningitidis | Serogroup | References | |
|---|---|---|---|
| MC58 | B | Wild type | [ |
| MC58siaD− | Capsule-deficient mutant | Isogenic siaD mutant | [ |
| WUE2120 | C | Wild type | [ |
| WUE2120siaD− | Capsule-deficient mutant | Isogenic siaD mutant | [ |
Fig. 1NmB and NmC strains activate p38 strongly, while Erk1/2 is only weakly activated. NmB and NmC strains as well as their capsule-deficient mutants activate the MAPK p38 when the basolateral side of the HIBCPP cells is infected, while the MAPK Erk1/2 is only weakly activated. The activation of the MAPK Erk1/2 (A) and p38 (B) was detected by Western blotting. HIBCPP cells were infected for 4 h with NmB and NmC wild type and capsule-deficient mutants in the inverted culture model of the HIBCPP cells from the basolateral side with a MOI of 100. Untreated cells (control) served as negative controls, cells treated with PMA or Anisomycin (Aniso) acted as positive controls for the activation of the Erk1/2 or p38 signal pathways, respectively. The blots were cropped to focus on the desired bands
Fig. 2MAPK are required for the infection of the HIBCPP cells by Nm wild type strains. HIBCPP cells were incubated for 1 h with the Erk1/2 and p38 inhibitors U0126, SB203580 or both inhibitors (U + SB) at a concentration of 25 μM each. Untreated cells acted as controls. The HIBCPP cells were infected for 4 h at a MOI 10 in the inverted culture. The intracellular bacteria could be quantified by double immunofluorescence staining (A). The integrity of the barrier function was determined over the course of the experiment by measuring the TEER values (B) and permeability for FITC inulin (C). *** extremely significant, p < 0.001; ** highly significant, p < 0.01; * significant, p < 0.05; when comparing the infection rate of treated cells with the infection rate in the control cells
Fig. 3Inhibition of Erk1/2 and p38 signalling impacts infection rates differently in absence of the capsule. The inhibition of the Erk1/2 signalling pathway leads to an increased infection by the capsule-deficient mutants of NmB and NmC, while inhibition of p38 signalling decreases the rate of infection of the NmC capsule-deficient mutant, but has no significant effect on the infection rates of the NmB capsule-deficient mutant. HIBCPP cells were incubated for 1 h with the inhibitors U0126, SB203580 or both inhibitors (U + SB) at a concentration of 25 μM each. Untreated cells acted as controls. The HIBCPP cells were infected for 4 h at a MOI 10 in the inverted culture. The intracellular bacteria could be quantified by double immunofluorescence staining (A). The integrity of the barrier function was determined over the course of the experiment by measuring the TEER values (B) and permeability for FITC inulin (C). *** extremely significant, p < 0.001; ** highly significant, p < 0.01; * significant, p < 0.05; when comparing the infection rate of treated cells with the infection rate in the control cells
Fig. 4The number of genes, which were regulated in HIBCPP cells after infection with NmB strains. The DEG were determined by comparing the HIBCPP cells infected with the NmB strains with the untreated controls. The DEG, which are regulated in both conditions as well as the DEG, which are only regulated in one of the conditions, are presented in the diagram
Summary of the DEG regulated by the NmB wild type strain and capsule deficient mutant
| Genesymbol | Genname | Fold change | |
|---|---|---|---|
| con vs. MC58 | con vs. MC58siaD− | ||
| IL1B | Interleukin 1 beta | 64.65 | 77.58 |
| CCL20 | C–C motif chemokine ligand 20 | 23.85 | 28.72 |
| IL17C | Interleukin 17C | 22.48 | 20.25 |
| CXCL2 | C-X-C motif chemokine ligand 2 | 20.76 | 19.03 |
| TNF | Tumor necrosis factor | 18.47 | 17.79 |
| IL6 | Interleukin 6 | 0.00 | 16.49 |
| CXCL1 | C-X-C motif chemokine ligand 1 | 15.80 | 16.35 |
| CXCL3 | C-X-C motif chemokine ligand 3 | 14.48 | 14.37 |
| CXCL8 | C-X-C motif chemokine ligand 8 | 14.03 | 14.45 |
| NFKBIZ | NFKB inhibitor zeta | 13.60 | 11.15 |
| CSF2 | Colony stimulating factor 2 | 13.01 | 15.08 |
| CCL2 | C–C motif chemokine ligand 2 | 12.47 | 13.89 |
| IL1A | Interleukin 1 alpha | 11.74 | 11.61 |
| ZC3H12A | Zinc finger CCCH-type containing 12A | 11.63 | 10.14 |
| TCIM | Transcriptional and immune response regulator | 9.73 | 10.53 |
| ICAM1 | Intercellular adhesion molecule 1 | 9.68 | 9.46 |
| RND1 | Rho family GTPase 1 | 9.04 | 9.08 |
| CXCL6 | C-X-C motif chemokine ligand 6 | 7.92 | 9.75 |
| CYP24A1 | Cytochrome P450 family 24 subfamily A member 1 | 7.64 | 8.70 |
| NFKBIA | NFKB inhibitor alpha | 7.46 | 7.34 |
| TNFAIP2 | TNF alpha induced protein 2 | 7.24 | 7.81 |
| SPIB | Spi-B transcription factor | 6.49 | |
| RASD1 | ras related dexamethasone induced 1 | 6.34 | |
| IGFBP1 | Insulin like growth factor binding protein 1 | 6.27 | |
| IL23A | Interleukin 23 subunit alpha | 6.10 | 8.24 |
| LIF | LIF interleukin 6 family cytokine | 5.97 | 5.01 |
| PTGS2 | Prostaglandin-endoperoxide synthase 2 | 5.89 | 5.68 |
| ANGPTL4 | Angiopoietin like 4 | 5.69 | 5.34 |
| ADORA2A | Adenosine A2a receptor | 5.44 | |
| ZFP36 | ZFP36 ring finger protein | 5.19 | 4.48 |
| C6orf222 | 4.98 | ||
| CX3CL1 | C-X3-C motif chemokine ligand 1 | 4.96 | 4.59 |
| TNFAIP3 | TNF alpha induced protein 3 | 4.94 | 4.45 |
| CSF1 | Colony stimulating factor 1 | 4.77 | |
| PI3 | Peptidase inhibitor 3 | 4.73 | |
| SERPINA3 | Serpin family A member 3 | 4.71 | |
| IER3 | Immediate early response 3 | 4.60 | 4.60 |
| SLC6A14 | Solute carrier family 6 member 14 | 4.59 | 4.97 |
| LTB | Lymphotoxin beta | 4.50 | 5.92 |
| TNFRSF6B | TNF receptor superfamily member 6b | 4.44 | |
| CEBPD | CCAAT enhancer binding protein delta | 4.40 | 4.47 |
| SOD2 | superoxide dismutase 2 | 4.30 | 5.21 |
| HILPDA | Hypoxia inducible lipid droplet associated | 4.27 | |
| MAFF | MAF bZIP transcription factor F | 4.21 | 4.13 |
Fig. 5Number of genes regulated in HIBCPP cells after Erk1/2 treatment and infection with NmB strains. The DEG were determined by comparing the HIBCPP cells infected with the NmB strains with the untreated controls as well as the treated control cells with the treated, infected cells. Shown are the DEG, which are regulated in both conditions, and the DEG, which are only regulated in one of the conditions
Summary of the DEG regulated by the NmB wild type strain in presence and absence of the inhibitor U0126
| Genesymbol | Genname | Fold change | |
|---|---|---|---|
| con vs. MC58 | con + U0126 vs. MC58 + U0126 | ||
| IL1B | INTERLEUKIN 1 beta | 64.65 | |
| CCL20 | C–C motif chemokine ligand 20 | 23.85 | 20.68 |
| IL17C | Interleukin 17C | 22.48 | 79.66 |
| CXCL2 | C-X-C motif chemokine ligand 2 | 20.76 | 20.30 |
| TNF | Tumor necrosis factor | 18.47 | 18.21 |
| CXCL1 | C-X-C motif chemokine ligand 1 | 15.80 | 16.79 |
| CXCL3 | C-X-C motif chemokine ligand 3 | 14.48 | 15.66 |
| CXCL8 | C-X-C motif chemokine ligand 8 | 14.03 | 16.17 |
| NFKBIZ | NFKB inhibitor zeta | 13.60 | 8.18 |
| CSF2 | colony stimulating factor 2 | 13.01 | |
| CCL2 | C–C motif chemokine ligand 2 | 12.47 | 11.80 |
| IL1A | Interleukin 1 alpha | 11.74 | |
| ZC3H12A | Zinc finger CCCH-type containing 12A | 11.63 | 12.04 |
| ANKRD37 | Ankyrin repeat domain 37 | 10.05 | |
| TCIM | Transcriptional and immune response regulator | 9.73 | 6.77 |
| ICAM1 | Intercellular adhesion molecule 1 | 9.68 | 7.98 |
| RND1 | Rho family GTPase 1 | 9.04 | 7.02 |
| CXCL6 | C-X-C motif chemokine ligand 6 | 7.92 | 7.67 |
| CYP24A1 | Cytochrome P450 family 24 subfamily A member 1 | 7,64 | |
| NFKBIA | NFKB inhibitor alpha | 7.46 | 7.33 |
| TNFAIP2 | TNF alpha induced protein 2 | 7.24 | 5.59 |
| IL23A | Interleukin 23 subunit alpha | 6.10 | |
| LIF | LIF interleukin 6 family cytokine | 5.97 | |
| PTGS2 | Prostaglandin-endoperoxide synthase 2 | 5.89 | |
| ADORA2A | Adenosine A2a receptor | 6.91 | |
| ADM | Adrenomedullin | 6.36 | |
| PFKFB4 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 | 6.34 | |
| ANGPTL4 | Angiopoietin like 4 | 5.69 | 7.59 |
| MIR210HG | MIR210 host gene | 5.63 | |
| IL4I1 | Interleukin 4 induced 1 | 5.48 | |
| CXCL10 | C-X-C motif chemokine ligand 10 | 5.40 | |
| ZFP36 | ZFP36 ring finger protein | 5.19 | |
| C6orf222 | 4.98 | 5.77 | |
| CX3CL1 | C-X3-C motif chemokine ligand 1 | 4.96 | 6.12 |
| TNFAIP3 | TNF alpha induced protein 3 | 4.94 | 5.03 |
| FBXL8 | F-box and leucine rich repeat protein 8 | 4.75 | |
| BHLHE40 | Basic helix-loop-helix family member e40 | 4.36 | |
| IER3 | IMMEDIATE early response 3 | 4.60 | |
| SLC6A14 | Solute carrier family 6 member 14 | 4.59 | |
| LTB | Lymphotoxin beta | 4.50 | |
| CEBPD | CCAAT enhancer binding protein delta | 4.40 | 4.01 |
| SOD2 | Superoxide dismutase 2 | 4.30 | 4.09 |
| MAFF | MAF bZIP transcription factor F | 4.21 | |
Summary of the DEG regulated by the NmB capsule-deficient mutant in presence and absence of the inhibitor U0126
| Genesymbol | Genname | Fold change | |
|---|---|---|---|
| con vs. MC58siaD− | con + U0126 vs. MC58siaD− + U0126 | ||
| IL1B | Interleukin 1 beta | 77.58 | 56.80 |
| CCL20 | C–C motif chemokine ligand 20 | 28.72 | 37.32 |
| IL17C | INTERLEUKIN 17C | 20.25 | 190.68 |
| CXCL2 | C-X-C motif chemokine ligand 2 | 19.03 | 26.60 |
| TNF | Tumor necrosis factor | 17.79 | 26.58 |
| IL6 | interleukin 6 | 16.49 | 8.56 |
| CXCL1 | C-X-C motif chemokine ligand 1 | 16.35 | 25.62 |
| CSF2 | colony stimulating factor 2 | 15.08 | 15.09 |
| CXCL8 | C-X-C motif chemokine ligand 8 | 14.45 | 26.67 |
| CXCL3 | C-X-C motif chemokine ligand 3 | 14.37 | 21.85 |
| CCL2 | C–C motif chemokine ligand 2 | 13.89 | 22.91 |
| ANKRD37 | Ankyrin repeat domain 37 | 12.78 | |
| IL1A | Interleukin 1 alpha | 11.61 | 28.19 |
| NFKBIZ | NFKB inhibitor zeta | 11.15 | 8.80 |
| TCIM | Transcriptional and immune response regulator | 10.53 | 10.40 |
| ZC3H12A | Zinc finger CCCH-type containing 12A | 10.14 | 14.27 |
| CXCL6 | C-X-C motif chemokine ligand 6 | 9.75 | 13.31 |
| IL4I1 | Interleukin 4 induced 1 | 9.49 | |
| ICAM1 | Intercellular adhesion molecule 1 | 9.46 | 11.60 |
| RND1 | Rho family GTPase 1 | 9.08 | 11.45 |
| CXCL10 | C-X-C motif chemokine ligand 10 | 8.81 | |
| CYP24A1 | Cytochrome P450 family 24 subfamily A member 1 | 8.70 | 4.63 |
| NOS2 | Nitric oxide synthase 2 | 8.64 | |
| IL23A | Interleukin 23 subunit alpha | 8.24 | 7.28 |
| TNFAIP2 | TNF alpha induced protein 2 | 7.81 | 8.00 |
| SAA2 | Serum amyloid A2 | 7.67 | |
| C6orf222 | 7.67 | ||
| GFPT2 | Glutamine-fructose-6-phosphate transaminase 2 | 7.60 | |
| PFKFB4 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 | 7.43 | |
| NFKBIA | NFKB inhibitor alpha | 7.34 | 9.29 |
| ADM | Adrenomedullin | 7.28 | |
| MIR210HG | MIR210 host gene | 6.90 | |
| SPIB | Spi-B transcription factor | 6.49 | |
| CHAC1 | ChaC glutathione specific gamma-glutamylcyclotransferase 1 | 6.48 | |
| RASD1 | Ras related dexamethasone induced 1 | 6.34 | |
| IGFBP1 | Insulin like growth factor binding protein 1 | 6.27 | |
| ANKK1 | Ankyrin repeat and kinase domain containing 1 | 5.99 | |
| LTB | Lymphotoxin beta | 5.92 | 5.95 |
| PTGS2 | Lymphotoxin beta | 5.68 | 4.50 |
| G0S2 | G0/G1 switch 2 | 5.46 | |
| ADORA2A | Adenosine A2a receptor | 5.44 | 11.67 |
| ZC3H12C | Zinc finger CCCH-type containing 12C | 5.44 | |
| ANGPTL4 | Angiopoietin like 4 | 5.34 | 10.50 |
| LOC101929444 | 5.29 | ||
| SOD2 | Superoxide dismutase 2 | 5.21 | 7.17 |
| LIF | LIF interleukin 6 family cytokine | 5.01 | |
| SLC6A14 | SOLUTE carrier family 6 member 14 | 4.97 | 6.04 |
| TNFRSF11B | TNF receptor superfamily member 11b | 4.90 | |
| CSF1 | Colony stimulating factor 1 | 4.77 | |
| PI3 | Peptidase inhibitor 3 | 4.73 | 4.62 |
| SERPINA3 | Serpin family A member 3 | 4.71 | 6.36 |
| EGLN3 | egl-9 family hypoxia inducible factor 3 | 4.70 | |
| IER3 | Immediate early response 3 | 4.60 | |
| CX3CL1 | C-X3-C motif chemokine ligand 1 | 4.59 | 8.78 |
| PFKFB3 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 | 4.59 | |
| RCAN1 | Regulator of calcineurin 1 | 4.54 | |
| ZFP36 | ZFP36 ring finger protein | 4.48 | |
| CEBPD | CCAAT enhancer binding protein delta | 4.47 | 4.97 |
| TNFAIP3 | TNF alpha induced protein 3 | 4.45 | 5.48 |
| TNFRSF6B | TNF receptor superfamily member 6b | 4.44 | 7.26 |
| BHLHE40 | Basic helix-loop-helix family member e40 | 4.38 | |
| HILPDA | Hypoxia inducible lipid droplet associated | 4.27 | 4.99 |
| PLAU | Plasminogen activator, urokinase | 4.02 | |
| MAFF | MAF bZIP transcription factor F | 4.13 | |
Validation of the MACE data by qPCR
| qPCR | Stdev | MACE | FDR p-value | |
|---|---|---|---|---|
| NFκβIZ | ||||
| Con vs. MC58 | 13.43 | 0.98 | 13.60 | 0.00 |
| Con + U0126 vs. MC58 + U0126 | 13.17 | 2.87 | 8.18 | 0.00 |
| Con vs. MC58siaD− | 11.16 | 3.79 | 11.15 | 0.00 |
Con + U0126 vs MC58siaD− + U | 11.99 | 4.21 | 8.80 | 0.00 |
| Zc3H12A | ||||
| Con vs. MC58 | 11.98 | 2.54 | 11.63 | 0.00 |
| Con + U0126 vs. MC58 + U0126 | 11.28 | 2.91 | 12.04 | 0.00 |
| Con vs. MC58siaD− | 11.81 | 2.83 | 10.14 | 0.00 |
Con + U0126 vs MC58siaD− + U | 10.40 | 2.35 | 14.27 | 0.00 |
| TNFα | ||||
| Con vs. MC58 | 14.35 | 2.89 | 18.47 | 0.00 |
| Con + U0126 vs. MC58 + U0126 | 17.08 | 1.72 | 18.21 | 0.00 |
| Con vs. MC58siaD− | 15.36 | 2.55 | 17.79 | 0.00 |
Con + U0126 vs MC58siaD− + U | 22.21 | 3.53 | 26.58 | 0.00 |
| IL6 | ||||
| Con vs. MC58 | 11.52 | 3.58 | - | - |
| Con + U0126 vs. MC58 + U0126 | 4.28 | 0.95 | - | - |
| Con vs. MC58siaD− | 16.16 | 5.62 | 16.49 | 0.02 |
Con + U0126 vs MC58siaD− + U | 7.73 | 3.32 | 8.56 | 0.02 |
| IL8 | ||||
| Con vs. MC58 | 18.21 | 8.86 | 14.03 | 0.00 |
| Con + U0126 vs. MC58 + U0126 | 30.36 | 8.88 | 16.17 | 0.00 |
| Con vs. MC58siaD− | 19.51 | 6.04 | 14.45 | 0.00 |
Con + U0126 vs MC58siaD− + U | 61.58 | 33.68 | 26.67 | 0.00 |
The relative fold changes were determined using the 2−ΔΔCT method. The mean values and standard deviations (Stdev) of the qPCR data as well as the fold change of the DEG and the FDR p-values are shown
Statistically overrepresented GO terms
| GO Term | Con vs MC58 | Con vs MC58siaD | Con + U0126 vs MC58 + U0126 | Con + U 0126 vs MC58siaD + U0126 | ||||
|---|---|---|---|---|---|---|---|---|
| p-value | Number annotated | p-value | Number Aannotated | p-value | Number annotated | p-value | Number annotated | |
| Cellular response to lipopolysaccharide | 1.64 × 10–20 | 16 | 3.03 × 10–20 | 17 | 1.49 × 10–15 | 13 | 1.35 × 10–19 | 18 |
| Cellular response to molecule of bacterial origin | 3.39 × 10–20 | 16 | 6.55 × 10–20 | 17 | 2.68 × 10–15 | 13 | 3.06 × 10–19 | 18 |
| Cytokine-mediated signalling pathway | 4.08 × 10–20 | 22 | 2.22 × 10–21 | 25 | 5.17 × 10–12 | 16 | 6.30 × 10–19 | 26 |
| Cellular response to interleukin-1 | 1.97 × 10–08 | 9 | 6.48 × 10–09 | 10 | 1.08 × 10–05 | 7 | 1.16 × 10–07 | 10 |
| Regulation of NIK/NF-kappaB signalling | 4.63 × 10–05 | 6 | 2.26 × 10–04 | 6 | 1.21 × 10–03 | 6 | ||
| NIK/NF-kappaB signalling | 5.84 × 10–04 | 6 | 2.78 × 10–03 | 6 | ||||
| Interleukin-6 production | 1.93 × 10–04 | 6 | 3.37 × 10–05 | 7 | 1.00 × 10–05 | 8 | ||
| Negative regulation of interleukin-6 production | 9.11 × 10–04 | 4 | 2.68 × 10–03 | 4 | 4.99 × 10–04 | 4 | 8.35 × 10–03 | 4 |
| Cell surface receptor signalling pathway | 1.82 × 10–10 | 25 | 7.24 × 10–12 | 30 | 1.73 × 10–06 | 20 | 3.69 × 10–09 | 32 |
| Signal transduction by protein phosphorylation | 3.11 × 10–03 | 10 | 4.96 × 10–03 | 11 | ||||
| MAPK cascade | 2.85 × 10–03 | 10 | 4.51 × 10–03 | 11 | ||||
| Positive regulation of MAPK cascade | 3.93 × 10–03 | 8 | 2.99 × 10–03 | 9 | ||||
| Regulation of ERK1 and ERK2 cascade | 7.13 × 10–04 | 7 | 4.27 × 10–03 | 7 | ||||
| JAK-STAT cascade | 8.91 × 10–03 | 5 | 1.56 × 10–03 | 6 | ||||
| Negative regulation of cell death | 2.99 × 10–08 | 15 | 6.62 × 10–11 | 19 | 1.79 × 10–04 | 11 | 1.76 × 10–06 | 17 |
| Response to tumour necrosis factor | 9.23 × 10–11 | 12 | 9.21 × 10–11 | 13 | 8.05 × 10–07 | 9 | 4.24 × 10–09 | 13 |
| Regulation of tumour necrosis factor production | 3.14 × 10–04 | 6 | 5.93 × 10–05 | 7 | 7.86 × 10–03 | 6 | ||
| Regulation of tumour necrosis factor superfamily cytokine production | 3.52 × 10–04 | 6 | 6.78 × 10–05 | 7 | 8.79 × 10–03 | 6 | ||
The GO terms were determined on the basis of the different lists of DEG. The analysis was carried out with the LAGO software and an upper limit of 0.01 was applied as p-value with a Bonferroni correction. The GO terms, the corrected p-value and the number of analysed genes in the respective GO terms (number of genes) are shown
Fig. 6A schematic summary of the data obtained with the Nm serogroup B strains. Wild type and the capsule-depleted mutant of NmB invade into HIBCPP cells representing the CP epithelium, with the mutant strain displaying higher invasion rates. Infection of HIBCPP cells by Nm leads to activation of the MAPKs Erk1/2 and p38. Inhibition of Erk1/2 and p38 with U0126 or SB203580, respectively, differentially influences the invasion by the different Nm strains. Whereas inhibition of Erk1/2 or p38 signalling reduces invasion by the wild type, invasion by the mutant is enhanced following inhibition of Erk1/2. Infection with wild type or capsule depleted Nm causes specific regulation of inflammatory response genes in the host cells, which is influenced by inhibition of Erk1/2. The impact on host cell processes cells was determined GO analysis. GO terms pointing to certain cellular processes, as production of IL-6 or regulation of TNF production, are lost specifically following Erk1/2 inhibition during infection with wild type Nm